

PUBLICATIONS 2022 ONCOSTAT

1. Sirab N, **Drubay D**, Maillé P, Popova T, Ngo C, Gentien D, Moktefi A, Soyeux-Porte P, Pelletier R, Reyes C, Henry E, Pouessel D, Vordos D, Lebret T, de Reyniès A, Paoletti X, Radvanyi F, Allory Y.
Multilayer spectrum of intratumoral heterogeneity in basal bladder cancer.
The Journal of Pathology. 2022 Jan;256(1):108-118. doi: 10.1002/path.5813.
Epub 2021 Nov 9. PMID : 34611919
2. Le Pechoux C, Pourel N, Barlesi F, Lerouge D, Antoni D, Lamezec B, Nestle U, Boisselier P, Dansin E, Paumier A, Peignaux K, Thillays F, Zalcmann G, Madelaine J, Pichon E, Larrouy A, Lavole A, Argo-Leignel D, Derollez M, Faivre-Finn C, Hatton MQ, Riesterer O, Bouvier-Morel E, **Dunant A**, Edwards JG, Thomas PA, Mercier O, **Bardet A**.
Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial.
The Lancet Oncology. 2022 Jan;23(1):104-114.
doi: 10.1016/S1470-2045(21)00606-9. Epub 2021 Dec 15. PMID : 34919827
3. **Bayle A**, Italiano A, Massard C, Blay JY, Marabelle A.
Basket trial health technology assessment requirements and limited access to innovations in oncology: The French paradox. 2022 Feb;162:128-129.
doi: 10.1016/j.ejca.2021.12.008. Epub 2022 Jan 1. European Journal of Cancer.
PMID : 34983014
4. **Ollier E**, **Blanchard P**, **Le Teuff G**, **Michiels S**.
Penalized Poisson model for network meta-analysis of individual patient time-to-event data. Statistics in Medicine. 2022 Jan 30;41(2):340-355.
doi: 10.1002/sim.9240. Epub 2021 Oct 28. PMID: 34710951
5. Martin M, **Hill C**, Bewley S, MacLennan AH, Braillon A.
Transgenerational adverse effects of valproate? A patient report from 90 affected families. Birth defects research. 2022 Jan 1;114(1):13-16.
doi: 10.1002/bdr2.1967. Epub 2021 Dec 5. PMID : 34866359

6. Dourthe ME, Phulpin A, **Auperin A**, Bosq J, Couec ML, Dartigues P, Ducassou S, Garnier N, Haouy S, Leblanc T, Leruste A, Paillard C, Rigaud C, Simonin M, Patte C, Minard-Colin V.
Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective study. *Haematologica*.
2022 Sep 1;107(9):2173-2182. doi: 10.3324/haematol.2021.280257
PMID: 35236054
7. Vigouret-Viant L, **Legoupil C**, **Bardet A**, Laurent C, Ducreux M, Laurent S, Mateus C, Dauchy S, Blot F.
Development of a Decision-Aid Form (DAF) for the stratification of care in a French comprehensive cancer center, a tool to support identification of care goals.
Annals of Palliative Medicine. 2022 Jun;11(6):1876-1887.
doi: 10.21037/apm-21-2854. Epub 2022 Feb 28. PMID: 35272472
8. Jannin A, Escande A, Al Ghuzlan A, **Blanchard P**, Hartl D, Chevalier B, Deschamps F, Lamartina L, Lacroix L, Dupuy C, Baudin E, Do Cao C, Hadoux J.
Anaplastic Thyroid Carcinoma: An Update. *Cancers (Basel)*.
2022 Feb 19;14(4):1061. doi: 10.3390/cancers14041061. PMID : 35205809
9. Gorphe P, Classe M, Ammari S, Garcia G, Even C, Casiraghi O, Breuskin I, Tao Y, Temam S, **Blanchard P**, Moya-Plana A.
Patterns of disease events and causes of death in patients with HPV-positive versus HPV-negative oropharyngeal carcinoma. *Radiotherapy and Oncology*.
2022 Mar;168:40-45. doi: 10.1016/j.radonc.2022.01.021. Epub 2022 Jan 29.
PMID : 35093406
10. Abbaci M, Conversano A, **Karimi M**, Mathieu MC, Rouffiac V, De Leeuw F, **Michiels S**, Laplace-Builhé C, Mazouni C.
Near-Infrared Fluorescence Axillary Reverse Mapping (ARM) Procedure in Invasive Breast Cancer: Relationship between Fluorescence Signal in ARM Lymph Nodes and Clinical Outcomes. *Cancers*. 2022 May 25;14(11):2614.
doi: 10.3390/cancers14112614. PMID: 35681595
11. **Atallah S**, Marc M, Schernberg A, Huguet F, Wagner I, Mäkitie A, Baujat B. Beyond Surgical Treatment in Adenoid Cystic Carcinoma of the Head and Neck: A Literature Review. *Cancer Management and Research*.
2022 Jun 4;14:1879-1890. doi: 10.2147/CMAR.S355663. eCollection 2022.
PMID : 35693117

12. Quivoron C, Tarabay A, Michot JM, **Paqès A**, Lecourt H, **Aupérin A**, Danu A, Lazarovici J, Rossignol J, Ghez D, Dartigues P, Vergé V, Massard C, Camara-Clayette V, Ribrag V, Sarkozy C.
Cell-free DNA sequencing as a potential screening tool for phase I targeted treatment in refractory/relapse diffuse large B cell lymphoma. *Haematologica*. 2022 Aug 1;107(8):1928-1932. doi: 10.3324/haematol.2021.280464. PMID : 35320922
13. Burke GAA, Minard-Colin V, **Aupérin A**, Alexander S, Pillon M, Delgado R, Zsíros J, Uyttebroeck A, Dartigues P, Miles RR, Kazanowska B, Chiang AK, Haouy S, Bollard CM, Csoka M, Wheatley K, Barkauskas DA, Adamson PC, Vassal G, Patte C, Gross TG. Reply to R. Lakhotia et al.
Journal of Clinical Oncology. 2022 Jun 20;40(18):2064-2066. doi: 10.1200/JCO.21.02912. Epub 2022 Apr 4. PMID : 35377710
14. Plais H, Labruyère M, Creutin T, Nay P, Plantefève G, Tapponnier R, Jonas M, Ngapmen NT, Le Guennec L, De Roquetaillade C, Argaud L, Jamme M, Goulenok C, Merouani K, Leclerc M, Sauneuf B, Shidasp S, Stoclin A, **Bardet A**, Mir O, **Ibrahimi N**, Llitjos JF.
Outcomes of Patients With Active Cancer and COVID-19 in the Intensive-Care Unit: A Multicenter Ambispective Study. *Frontiers in Oncology*. 2022 Mar 10;12:858276. doi: 10.3389/fonc.2022.858276. eCollection 2022. PMID : 35359407
15. Charles C, **Bardet A**, **Larive A**, Gorwood P, Ramoz N, Thomas E, Viari A, Rousseau-Tsangaris M, Dumas A, Menvielle G, Everhard S, Martin AL, Gbenou SY, Havas J, El-Mouhebb M, Di Meglio A, André F, Pistilli B, Coutant C, Cottu P, Mérimèche A, Lerebours F, Tredan O, Vanlemmens L, Jouannaud C, Levy C, Vaz-Luis I, **Michiels S**, Dauchy S.
Characterization of Depressive Symptoms Trajectories After Breast Cancer Diagnosis in Women in France. *JAMA Network Open*. 2022 Apr 1;5(4):e225118. doi: 10.1001/jamanetworkopen.2022.5118. PMID : 35420663
16. Chapuis N, **Ibrahimi N**, Belmondo T, Goulvestre C, Berger AE, Mariaggi AA, Andrieu M, Chenevier-Gobeaux C, **Bayle A**, Campos L, Cheurfa C, Chocron R, Diehl JL, Doumenc B, Duchemin J, Duprat M, François F, Gendron N, Mirault T, Pène F, Philippe A, Pommeret F, Sanchez O, Smadja DM, Szwebel TA, Silvin A, Ginhoux F, Lacroix L, Jules-Clément G, Rapeteramana S, Mavier C, Steller L, Perniconi B, André F, **Drubay D**, Fontenay M, Hüe S, Paul S, Solary E. Dynamics of circulating calprotectin accurately predict the outcome of moderate COVID-19 patients. *EBioMedicine*. 2022 Jun;80:104077. doi: 10.1016/j.ebiom.2022.104077. Epub 2022 May 26. PMID : 35644124

17. Lee RJ, Wysocki O, Zhou C, Shotton R, Tivey A, Lever L, Woodcock J, Albiges L, Angelakas A, Arnold D, Aung T, Banfill K, Baxter M, Barlesi F, **Bayle A**, Besse B, Bhogal T, Boyce H, Britton F, Calles A, Castelo-Branco L, Copson E, Croitoru AE, Dani SS, Dickens E, Eastlake L, Fitzpatrick P, **Foulon S**, Frederiksen H, Frost H, Ganatra S, Gennatas S, Glenthøj A, Gomes F, Graham DM, Hague C, Harrington K, Harrison M, Horsley L, Hoskins R, Huddar P, Hudson Z, Jakobsen LH, Joharatnam-Hogan N, Khan S, Khan UT, Khan K, Massard C, Maynard A, McKenzie H, Michielin O, Mosenthal AC, Obispo B, Patel R, Pentheroudakis G, Peters S, Rieger-Christ K, Robinson T, Rogado J, Romano E, Rowe M, Sekacheva M, Sheehan R, Stevenson J, Stockdale A, Thomas A, Turtle L, Viñal D, Weaver J, Williams S, Wilson C, Palmieri C, Landers D, Cooksley T; ESMO Co-Care, Dive C, Freitas A, Armstrong AC.
Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital.
JCO Clinical Cancer Informatics. 2022 May;6:e2100177.
doi: 10.1200/CCI.21.00177. PMID : 35609228
18. **Blanchard P**, Biau J, Huguet F, Racadot S, Berthold C, Wong-Hee-Kam S, Biston MC, Maingon P. Radiotherapy for nasopharyngeal cancer.
Cancer Radiothérapie. Feb-Apr 2022;26(1-2):168-173.
doi: 10.1016/j.canrad.2021.08.009. Epub 2021 Dec 22. PMID : 34953699
19. Hannoun-Lévi JM, Chargari C, **Blanchard P**, Pommier P, Ollivier L, Ferré M, Peiffert D. Best practice in brachytherapy. Cancer Radiothérapie. Feb-Apr 2022;26(1-2):29-33. doi: 10.1016/j.canrad.2021.09.003.
Epub 2021 Dec 22. PMID : 34953690
20. Biau J, Pointreau Y, **Blanchard P**, Khampan C, Giraud P, Lapeyre M, Maingon P. Radiotherapy for laryngeal cancers. Cancer Radiothérapie. Feb-Apr 2022;26(1-2):206-212. doi: 10.1016/j.canrad.2021.09.004.
Epub 2021 Dec 22. PMID : 34953705
21. Hennequin C, Azria D, **Blanchard P**, Créhange G, Deutsch É, Lisbona A, Moyal É, Pasquier D, Roca L, Supiot S, Giraud P. Specificities of clinical research in radiotherapy. Cancer Radiothérapie. Feb-Apr 2022;26(1-2):104-107. doi: 10.1016/j.canrad.2021.11.011.
Epub 2021 Dec 23. PMID : 34953712

22. de Crevoisier R, Supiot S, Créhange G, Pommier P, Latorzeff I, Chapet O, Pasquier D, **Blanchard P**, Schick U, Marchesi V, Sargos P, Hennequin C.
External radiotherapy for prostatic cancers. *Cancer Radiothérapie*.
Feb-Apr 2022;26(1-2):329-343. doi: 10.1016/j.canrad.2021.11.017.
Epub 2021 Dec 23. PMID : 34955419
23. Pommier P, Ferré M, **Blanchard P**, Martin É, Peiffert D, Robin S, Hannoun-Lévi JM, Marchesi V, Cosset JM.
Prostate cancer brachytherapy: SFRO guidelines 2021. *Cancer Radiothérapie*.
Feb-Apr 2022;26(1-2):344-355. doi: 10.1016/j.canrad.2021.11.019.
Epub 2021 Dec 23. PMID : 34955422
24. Bossi A, **Blanchard P**.
The Post-Prostatectomy Setting: What to Do and When to Do....
International Journal of Radiation Oncology, Biology, Physics.
2022 Jun 1;113(2):254. doi: 10.1016/j.ijrobp.2021.03.038. PMID : 35569472
25. Gorphe P, Moya-Plana A, Guerlain J, Tao Y, Nguyen F, Breuskin I, **Blanchard P**, Temam S.
Disease-free time stratification in locally recurrent head and neck carcinoma after definitive radiotherapy or chemoradiotherapy.
European Archives of Oto-Rhino-Laryngology. 2022 Jun;279(6):3063-3069.
doi: 10.1007/s00405-021-07116-6. Epub 2021 Oct 14. PMID : 34648050
26. Biau J, Nutting C, Langendijk JA, Frédéric-Moreau T, Thariat J, Piram L, Bellini R, Saroul N, Pham Dang N, O'Sullivan B, Giralt J, **Blanchard P**, Bourhis J, Lapeyre M.
Radiographic-anatomy, natural history and extension pathways of parotid and submandibular gland cancers. *Radiotherapy and Oncology*.
2022 May;170:48-54. doi: 10.1016/j.radonc.2022.03.005. Epub 2022 Mar 11.
PMID : 35288225
27. Flippot R, Patrikidou A, Aldea M, Colomba E, Lavaud P, Albigès L, Naoun N, **Blanchard P**, Terlizzi M, Garcia C, Bernard-Tessier A, Fuerea A, Di Palma M, Escudier B, Lorient Y, Baciarello G, Fizazi K.
PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer.
Drugs. 2022 May;82(7):719-733. doi: 10.1007/s40265-022-01703-5.
Epub 2022 May 5. PMID : 35511402
28. Terlizzi M, Limkin EJ, Moukasse Y, **Blanchard P**.
Adjuvant or Salvage Radiation Therapy for Prostate Cancer after Prostatectomy: Current Status, Controversies and Perspectives. *Cancers (Basel)*.
2022 Mar 26;14(7):1688. doi: 10.3390/cancers14071688.
PMID : 35406460

29. Terrisse S, Goubet AG, Ueda K, Thomas AM, Quiniou V, Thelemaque C, Dunsmore G, Clave E, Gamat-Huber M, Yonekura S, Ferrere G, Rauber C, Pham HP, Fahrner JE, Pizzato E, Ly P, Fidelle M, Mazzenga M, Costa Silva CA, Armanini F, Pinto F, Asnicar F, Daillère R, Derosa L, Richard C, **Blanchard P**, Routy B, Culine S, Opolon P, Silvin A, Ginhoux F, Toubert A, Segata N, McNeel DG, Fizazi K, Kroemer G, Zitvogel L.
Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer.
Journal for Immunotherapy of Cancer. 2022 Mar;10(3):e004191.
doi: 10.1136/jitc-2021-004191. PMID: 35296557
30. Dinia A, Ammari S, Filtes J, Classe M, Moya-Plana A, Bidault F, Temam S, **Blanchard P**, Lassau N, Gorphe P.
Events prediction after treatment in HPV-driven oropharyngeal carcinoma using machine learning. European Journal of Cancer. 2022 Aug;171:106-113.
doi: 10.1016/j.ejca.2022.05.003. Epub 2022 Jun 14. PMID : 35714450
31. Kissel M, Pounou A, Ka K, Alexis A, Irani J, Jereczek-Fossa BA, Terlizzi M, Bossi A, **Blanchard P**. Efficacy and toxicity following salvage high-dose-rate brachytherapy for locally recurrent prostate cancer after radiotherapy. Brachytherapy. 2022 Jul-Aug;21(4):424-434.
doi: 10.1016/j.brachy.2022.01.005. Epub 2022 Mar 21. PMID : 35331666
32. Moya-Plana A, Tselikas L, Lambotte O, Temam S, De Baere T, Deutsch E, Barlesi F, **Blanchard P**, Levy A.
Postgraduate oncology educational shifts during the COVID-19 pandemic: results of faculty and medical student surveys. ESMO Open. 2022 Apr;7(2):100451.
doi: 10.1016/j.esmoop.2022.100451. Epub 2022 Mar 2. PMID : 35427841
33. de Kerangal Q, **Kapso R**, Morinière S, Laure B, **Bonastre J**, Moya-Plana A. Sentinel lymph node biopsy versus selective neck dissection in patients with early oral squamous cell carcinoma: A cost analysis.
Journal of Stomatology, Oral and Maxillofacial Surgery.
2022 Jun;123(3):372-376. doi: 10.1016/j.jormas.2021.05.003.
Epub 2021 May 14. PMID : 34000437
34. Or Z, **Rococco E**, Touré M, **Bonastre J**.
Impact of Competition Versus Centralisation of Hospital Care on Process Quality: A Multilevel Analysis of Breast Cancer Surgery in France.
International Journal of Health Policy and Management.
2022 Apr 1;11(4):459-469. doi: 10.34172/ijhpm.2020.179. PMID : 33008262

35. Di Meglio A, Martin E, Crane TE, Charles C, Barbier A, Raynard B, **Mangin A**, Tredan O, Bouleuc C, Cottu PH, Vanlemmens L, Segura-Djezzar C, Lesur A, Pistilli B, Joly F, Ginsbourger T, Coquet B, Pauporte I, Jacob G, Sirven A, **Bonastre J**, Ligibel JA, **Michiels S**, Vaz-Luis I.
A phase III randomized trial of weight loss to reduce cancer-related fatigue among overweight and obese breast cancer patients: MEDEA Study design. *Trials*. 2022 Mar 4;23(1):193. doi: 10.1186/s13063-022-06090-6.
PMID : 35246219
36. Leboulleux S, Bournaud C, Chougnet CN, Zerdoud S, Al Ghuzlan A, Catargi B, Do Cao C, Kelly A, Barge ML, Lacroix L, Dygai I, Vera P, Rusu D, Schneegans O, Benisvy D, Klein M, Roux J, Eberle MC, Bastie D, Nascimento C, Giraudet AL, Le Moullec N, Bardet S, Drui D, Roudaut N, Godbert Y, Morel O, Drutel A, Lamartina L, Schvartz C, Velayoudom FL, Schlumberger MJ, Leenhardt L, **Borget I**.
Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer. *The New England Journal of Medicine*. 2022 Mar 10;386(10):923-932.
doi: 10.1056/NEJMoa2111953. PMID : 35263518
37. Lamartina L, Leboulleux S, **Borget I**, Schlumberger M.
Global thyroid estimates in 2020. *The Lancet Diabetes & Endocrinology*. 2022 Apr;10(4):235-236. doi: 10.1016/S2213-8587(22)00048-1.
Epub 2022 Mar 7. PMID : 35271820
38. Leboulleux S, Schlumberger MJ, **Borget I**.
Thyroidectomy without Radioiodine in Low-Risk Thyroid Cancer. Reply. *The New England Journal of Medicine*. 2022 Jun 2;386(22):2155.
doi: 10.1056/NEJMc2204553. PMID : 35648717
39. Luyten J, Connolly MP, Verbeke E, Buhler K, Scotland G, Lispi M, Revelli A, **Borget I**, Cedrin-Durnerin I, D'Hooghe T.
Economic evaluation of Medically Assisted Reproduction: An educational overview of methods and applications for healthcare professionals. *Best practice & research - Clinical obstetrics & gynaecology*. 2022 Dec;85(Pt B):217-228. doi: 10.1016/j.bpobgyn.2022.01.008. Epub 2022 Feb 2.
PMID : 35219590
40. Farah L, Magne N, Martelli N, Sotton S, Zerbib M, **Borget I**, Scher N, Guetta T, Chargari C, Bauduceau O, Toledano A.
Robot-Assisted Surgery vs Robotic Stereotactic Body Radiotherapy in Prostate Cancer: A Cost-Utility Analysis. *Frontiers in Oncology*. 2022 May 24;12:834023.
doi: 10.3389/fonc.2022.834023. eCollection 2022. PMID : 35686090

41. Leboulleux S, **Borget I**, Schlumberger M.
Post-operative radioactive iodine administration in patients with low-risk thyroid cancer. *Nature Reviews Endocrinology*. 2022 Oct;18(10):585-586.
doi: 10.1038/s41574-022-00709-z. PMID : 35725924
42. Baciarello G, Delva R, Gravis G, Tazi Y, Beuzeboc P, Gross-Goupil M, Bompas E, Joly F, Greilsamer C, Hon TNT, Barthelemy P, Culine S, Berdah JF, Deblock M, Ratta R, Flechon A, Cheneau C, **Maillard A**, Martineau G, **Borget I**, Fizazi K; Groupe d'Etude des Tumeurs Uro-Genitales (GETUG).
Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial. *European Urology*. 2022 Mar;81(3):234-240. doi: 10.1016/j.eururo.2021.10.016.
Epub 2021 Nov 14. PMID : 34789394
43. Gascon P, **Borget I**, Comet A, Carton L, Matonti F, Dupont-Benjamin L.
Costs comparison of treating diabetic macular edema with aflibercept, ranibizumab or dexamethasone at 1 year in France (INVICOST study). *European Journal of Ophthalmology*. 2022 May;32(3):1702-1709.
doi: 10.1177/11206721211033480. Epub 2021 Jul 20. PMID : 34284605
44. **Grumberg V**, Chouaïd C, Cotté FE, Jouaneton B, Jolivel R, Gaudin AF, Reynaud D, Assié JB, **Borget I**.
Long-term hospital resource utilization and associated costs of care for patients initiating nivolumab in advanced non-small cell lung cancer in France. *Journal of medical economics*. Jan-Dec 2022;25(1):691-699.
doi: 10.1080/13696998.2022.2079291. PMID : 35587018
45. Girault I, Adam J, Shen S, Roy S, **Brard C**, Faouzi S, Routier E, Lupu J, Warren S, Sorg K, Ong S, Morel P, Scoazec J-Y, Vagner S, Robert C.
A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma. *Clinical Cancer Research*. 2022 Feb 1;28(3):518-525. doi: 10.1158/1078-0432.CCR-21-1229.
Epub 2021 Nov 16. PMID : 34785583
46. Aupomerol M, **Chaltiel D**, Pautier P, Wehrer D, Véron L, Degoussée L, Fasse L, Guérault-Accolas L, Di Meglio A, Scotté F, De-Jesus A, Vaz-Luis I, Delalogue S, Lambertini M, Pistilli B.
Breast Cancer Patients' Experience and Wishes Regarding Communication on Sexual Health: The BEROSE Study. *Cancer Investigation*. 2022 Jul;40(6):483-493. doi: 10.1080/07357907.2022.2066112.
Epub 2022 May 1. PMID : 35468006

47. **Chaltiel D**, Julia C, Chaltiel R, Baudry J, Touvier M, Deschamps V, Latino-Martel P, Fezeu L, Hercberg S, Kesse-Guyot E.
Prospective association between adherence to the 2017 French dietary guidelines and risk of death, CVD and cancer in the NutriNet-Santé cohort.
The British Journal of Nutrition. 2022 Feb 28;127(4):619-629.
doi: 10.1017/S0007114521001367. Epub 2021 May 21. PMID : 34016201
48. Bouaoud J, Temam S, Galmiche L, **Cozic N**, Bolle S, Belhous K, Kolb F, Qassemyar Q, Bidault F, Couloigner V, Picard A, **Le Deley MC**, Mahier-Ait Oukhtar C, Gaspar N, Kadlub N.
Head and neck Ewing sarcoma: French surgical practice analysis pleads for surgery centralization. Journal of cranio-maxillofacial Surgery.
2022 May;50(5):439-448. doi: 10.1016/j.jcms.2021.01.030. Epub 2021 Feb 6.
PMID : 35063337
49. Derosa L, Routy B, Thomas AM, Iebba V, Zalcman G, Friard S, Mazieres J, Audigier-Valette C, Moro-Sibilot D, Goldwasser F, Silva CAC, Terrisse S, Bonvalet M, Scherpereel A, Pegliasco H, Richard C, Ghiringhelli F, Elkrief A, Desilets A, Blanc-Durand F, Cumbo F, Blanco A, Boidot R, Chevrier S, Daillère R, Kroemer G, Alla L, Pons N, Le Chatelier E, Galleron N, Roume H, Dubuisson A, Bouchard N, Messaoudene M, **Drubay D**, Deutsch E, Barlesi F, Planchard D, Segata N, Martinez S, Zitvogel L, Soria JC, Besse B.
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nature Medicine.
2022 Feb;28(2):315-324. doi: 10.1038/s41591-021-01655-5. Epub 2022 Feb 3.
PMID : 35115705
50. Loi S, Salgado R, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, **Drubay D**, Lemonnier J, Sotiriou C, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, André F, Denkert C, Piccart M, **Roblin E**, **Michiels S**.
Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer. NPJ Breast Cancer. 2022 Jan 11;8(1):3.
doi: 10.1038/s41523-021-00362-1. PMID : 35017545
51. Marchais A, Marques da Costa ME, Job B, **Abbas R**, **Drubay D**, Piperno-Neumann S, Fromigué O, Gomez-Brouchet A, Redini F, Droit R, Lervat C, Entze-Werle N, Pacquement H, Devoldere C, Cupissol D, Bodet D, Gandemer V, Berger M, Marec-Berard P, Jimenez M, Vassal G, Geoerger B, Brugières L, Gaspar N.
Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis.
Cancer Research. 2022 Mar 15;82(6):974-985.
doi: 10.1158/0008-5472.CAN-20-4189. PMID : 35078815

52. Fahrner JE, Lahmar I, Goubet AG, Haddad Y, Carrier A, Mazzenga M, **Drubay D**, Alves Costa Silva C; Lyon COVID Study Group, de Sousa E, Thelemaque C, Melenotte C, Dubuisson A, Geraud A, Ferrere G, Birebent R, Bigenwald C, Picard M, Cerbone L, Lérias JR, Laparra A, Bernard-Tessier A, Kloeckner B, Gazzano M, Danlos FX, Terrisse S, Pizzato E, Flament C, Ly P, Tartour E, Benhamouda N, Meziani L, Ahmed-Belkacem A, Miyara M, Gorochov G, Barlesi F, Trubert A, Ungar B, Estrada Y, Pradon C, Gallois E, Pommeret F, Colomba E, Lavaud P, Deloger M, Droin N, Deutsch E, Gachot B, Spano JP, Merad M, Scotté F, Marabelle A, Griscelli F, Blay JY, Soria JC, Merad M, André F, Villemonteix J, Chevalier MF, Caillat-Zucman S, Fenollar F, Guttman-Yassky E, Launay O, Kroemer G, La Scola B, Maeurer M, Derosa L, Zitvogel L.
The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals. *Cancer Discovery*. 2022 Apr 1;12(4):958-983.
doi: 10.1158/2159-8290.CD-21-1441. PMID : 35179201
53. Roux C, Boileve A, **Faron M**, Lamartina L, Delpla A, Tselikas L, Durand-Labrunie J, Hescot S, de Baere T, Hadoux J, Deschamps F, Baudin E.
Loco-Regional Therapies in Oligometastatic Adrenocortical Carcinoma. *Cancers*. 2022 May 31;14(11):2730. doi: 10.3390/cancers14112730. PMID : 35681708
54. Le Roy C, Le Péchoux C, Alapetite C, Bahleda R, Ngo C, Honoré C, **Faron M**, Le Cesne A, Mir O, Haie-Meder C, Chargari C, Levy A.
Inoperable scalp cutaneous angiosarcoma: Complete response after definitive external beam radiation therapy - brachytherapy association. *Oral Oncology*. 2022 Feb;125:105715. doi: 10.1016/j.oraloncology.2022.105715.
Epub 2022 Jan 11. PMID : 35030408
55. Ngo C, Grinda T, Boilève A, Levy A, Le Pechoux C, Haddag L, Valent A, Lazure T, Briand S, Honoré C, **Faron M**, Mir O, Bahleda R, Verret B, Le Cesne A.
Durable response to crizotinib in metastatic angiomatoid fibrous histiocytoma with EWSR1-CREB1 fusion and ALK overexpression. *Annals of Oncology*. 2022 Aug;33(8):848-850. doi: 10.1016/j.annonc.2022.05.003. Epub 2022 May 12.
PMID : 35568279
56. Tselikas L, Dardenne A, de Baere T, **Faron M**, Ammari S, Farhane S, Suzzoni S, Danlos FX, Raoult T, Susini S, Al Shatti N, Mouraud S, Deschamps F, Kobe A, Delpla A, Roux C, Baldini C, Soria JC, Barlesi F, Massard C, Robert C, Champiat S, Marabelle A.
Feasibility, safety and efficacy of human intra-tumoral immuno-therapy. Gustave Roussy's initial experience with its first 100 patients.
European Journal of Cancer. 2022 Sep;172:1-12. doi: 10.1016/j.ejca.2022.05.024.
Epub 2022 Jun 18. PMID : 35724442

57. Hescot S, **Faron M**, Kordahi M, Do Cao C, Naman A, Lamartina L, Hadoux J, Leboulleux S, Pattou F, Aubert S, Scoazec JY, Al Ghuzlan A, Baudin E. Screening for Prognostic Biomarkers in Metastatic Adrenocortical Carcinoma by Tissue Micro Arrays Analysis Identifies P53 as an Independent Prognostic Marker of Overall Survival. *Cancers*. 2022 Apr 29;14(9):2225. doi: 10.3390/cancers14092225. PMID : 35565353
58. Fizazi K, **Foulon S**, Carles J, Roubaud G, McDermott R, Fléchon A, Tombal B, Supiot S, Berthold D, Ronchin P, Kacso G, Gravis G, Calabro F, Berdah JF, Hasbini A, Silva M, Thiery-Vuillemin A, Latorzeff I, Mourey L, Laguerre B, Abadie-Lacourtoisie S, Martin E, El Kouri C, Escande A, Rosello A, Magne N, Schlurmann F, Priou F, Chand-Fouche ME, Freixa SV, Jamaluddin M, Rieger I, Bossi A; PEACE-1 investigators. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. *The Lancet*. 2022 Apr 30;399(10336):1695-1707. doi: 10.1016/S0140-6736(22)00367-1. Epub 2022 Apr 8. PMID : 35405085
59. Petrovic D, Bodinier B, Dagnino S, Whitaker M, **Karimi M**, Campanella G, Haugdahl Nøst T, Polidoro S, Palli D, Krogh V, Tumino R, Sacerdote C, Panico S, Lund E, Dugué PA, Giles GG, Severi G, Southey M, Vineis P, Stringhini S, Bochud M, Sandanger TM, Vermeulen RCH, Guida F, Chadeau-Hyam M. Epigenetic mechanisms of lung carcinogenesis involve differentially methylated CpG sites beyond those associated with smoking. *European Journal of Epidemiology*. 2022 Jun;37(6):629-640. doi: 10.1007/s10654-022-00877-2. Epub 2022 May 20. PMID : 35595947
60. **Early Breast Cancer Trialists' Collaborative Group (EBCTCG)**. Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. *The Lancet Oncology*. 2022 Mar;23(3):382-392. doi: 10.1016/S1470-2045(21)00758-0. Epub 2022 Feb 3. PMID : 35123662
61. Defachelles AS, Bogart E, Casanova M, Merks JHM, Bisogno G, Calareso G, Melcon SG, Gatz SA, **Le Deley MC**, McHugh K, Probst A, Rocourt N, van Rijn RR, Minard-Colin V, Chisholm JC. Reply to H. B et al. 2022 Mar 20;40(9):1030-1032. *Journal of Clinical Oncology*. doi: 10.1200/JCO.21.02612. Epub 2022 Feb 7. PMID : 35130027

62. Penel N, Bonvalot S, Bimbai AM, Meurgey A, Le Loarer F, Salas S, Piperno-Neumann S, Chevreau C, Boudou-Rouquette P, Dubray-Longeras P, Kurtz JE, Guillemet C, Bompas E, Italiano A, Le Cesne A, Orbach D, Thery J, **Le Deley MC**, Blay JY, Mir O.
Lack of prognostic value of CTNNB1 mutation profile in desmoid-type fibromatosis. *Clinical Cancer Research*. 2022 Sep 15;28(18):4105-4111.
doi: 10.1158/1078-0432.CCR-21-4235.PMID : 35294527
63. Lorient Y, **Texier M**, Culine S, Fléchon A, Thiery-Vuillemin A, Gravis G, Geoffrois L, Chevreau C, Gross-Goupil M, Barthelemy P, Bompas E, Mahammedi H, Laguerre B, Lacourtoisie SA, Helissey C, Ladoire S, Abraham C, Massard C, Grimaldi S, Fizazi K. The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. *European urology*. 2022 Aug;82(2):172-179. doi: 10.1016/j.eururo.2022.04.031.
Epub 2022 May 20. PMID : 35599187
64. Riudavets M, Naigeon M, **Texier M**, Dorta M, Barlesi F, Mazieres J, Varga A, Cassard L, Boselli L, Grivel J, NgoCamus M, Lacroix L, Mezquita L, Besse B, Chaput N, Planchard D.
Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial. *Lung Cancer*. 2022 Apr; 166: 255-264. doi: 10.1016/j.eururo.2022.04.03.
Epub 2021 Dec 3. PMID : 34953624
65. Baldini C, Danlos FX, Varga A, **Texier M**, Halse H, Mouraud S, Cassard L, Champiat S, Signolle N, Vuagnat P, Martin-Romano P, Michot JM, Bahleda R, Gazzah A, Boselli L, Bredel D, Grivel J, Mohamed-Djalim C, Escriou G, Grynszpan L, Bigorgne A, Rafie S, Abbassi A, Ribrag V, Postel-Vinay S, Hollebecque A, Susini S, Farhane S, Lacroix L, Parpaleix A, Laghouati S, Zitvogel L, Adam J, Chaput N, Soria JC, Massard C, Marabelle A.
Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers. *Journal of Experimental & Clinical Cancer Research*. 2022 Jul 7;41(1):217.
doi: 10.1186/s13046-022-02423-0. PMID : 35794623
66. Doyen J, Besse B, **Texier M**, Bonnet N, Levy A.
PD-1 iNhibitor and chemotherapy with concurrent IRradiation at VARied tumor sites in advanced Non-small cell lung cAncer: the Prospective Randomized Phase 3 NIRVANA-Lung Trial. *Clinical Lung Cancer*. 2022 May; 23(3):e252-e256. doi: 10.1016/j.clcc.2021.10.008. Epub 2021 Oct 24.
PMID : 34810130

67. Schenone L, Houillier C, **Tanguy ML**, Choquet S, Agbetiafa K, Ghesquières H, Damaj G, Schmitt A, Bouabdallah K, Ahle G, Gressin R, Cornillon J, Houot R, Marolleau JP, Fornecker LM, Chinot O, Peyrade F, Bouabdallah R, Moluçon-Chabrot C, Gyan E, Chauchet A, Casasnovas O, Oberic L, Delwail V, Abraham J, Roland V, Waultier-Rascalou A, Willems L, Morschhauser F, Fabbro M, Ursu R, Thieblemont C, Jardin F, Tempescul A, Malaise D, Touitou V, Nichelli L, Le Garff-Tavernier M, Plessier A, Bourget P, Bonmati C, Wantz-Mézières S, Giordan Q, Dorvaux V, Charron C, Jabeur W, Hoang-Xuan K, Taillandier L, Soussain C; French network for oculocerebral lymphoma (LOC network).
Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network.
Bone marrow transplantation. 2022 Jun;57(6):966-974.
doi: 10.1038/s41409-022-01648-z. Epub 2022 Apr 14. PMID: 35422077
68. **Pages A**, Costa N, Gonzalez-Bautista E, Mounie M, Juillard-Condât B, Molinier L, Cestac P, Rolland Y, Vellas Y, De Souto Barreto P, MAPT/DSA Group.
Screening for deficits on intrinsic capacity domains and associated healthcare costs. Archives of Gerontology and Geriatrics. 2022 May-Jun;100:104654.
doi: 10.1016/j.archger.2022.104654. Epub 2022 Feb 7.
PMID : 35193041
69. Ayaden N, Sitbon P, **Pages A**, Tselikas L, Bourgain JL.
Pain after Interventional Radiology in Oncology: A Case-Control Study from a 5-Year Cohort. Cancers (Basel). 2022 May 24;14(11):2576.
doi: 10.3390/cancers14112576. PMID : 35681559
70. **Abbas R**, Wason J, **Michiels S**, **Le Teuff G**. A two-stage drop-the-losers design for time-to-event outcome using a historical control arm.
Pharmaceutical statistics. 2022 Jan;21(1):268-288. doi: 10.1002/pst.2168.
Epub 2021 Sep 8. PMID: 34496117
71. Gregorich M, Melograna F, **Sunqvist M**, **Michiels S**, Van Steen K, Heinze G.
Individual-specific networks for prediction modelling - A scoping review of methods. BMC Medical Research Methodology. 2022 Mar 6;22(1):62.
doi: 10.1186/s12874-022-01544-6. PMID: 35249534

72. Berlanga P, Pierron G, Lacroix L, Chicard M, Adam de Beaumais T, Marchais A, Harttrampf AC, Iddir Y, **Larive A**, Soriano Fernandez A, Hezam I, **Chevassus C**, Bernard V, Cotteret S, Scoazec JY, Gauthier A, Abbou S, Corradini N, André N, Aerts I, Thebaud E, Casanova M, Owens C, Hladun-Alvaro R, **Michiels S**, Delattre O, Vassal G, Schleiermacher G, Geoerger B.
The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies. *Cancer discovery*. 2022 May 2;12(5):1266-1281. doi: 10.1158/2159-8290.CD-21-1136. PMID : 35292802
73. Di Meglio A, Havas J, Gbenou AS, Martin E, El-Mouhebb M, Pistilli B, Menvielle G, Dumas A, Everhard S, Martin AL, Cottu PH, Lerebours F, Coutant C, Lesur A, Tredan O, Soulie P, Vanlemmens L, Joly F, Delalogue S, Ganz PA, André F, Partridge AH, Jones LW, **Michiels S**, Vaz-Luis I.
Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy. *Journal of Clinical Oncology*. 2022 Sep 20;40(27):3190-3204. doi: 10.1200/JCO.21.00277. Epub 2022 Apr 21. PMID: 35446677
74. Vaz-Luis I, Di Meglio A, Havas J, El-Mouhebb M, Lapidari P, Presti D, Soldato D, Pistilli B, Dumas A, Menvielle G, Charles C, Everhard S, Martin AL, Cottu PH, Lerebours F, Coutant C, Dauchy S, Delalogue S, Lin NU, Ganz PA, Partridge AH, André F, **Michiels S**.
Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis. *Journal of Clinical Oncology*. 2022 Jul 1;40(19):2148-2162. doi: 10.1200/JCO.21.01958. Epub 2022 Mar 15. PMID: 35290073
75. Ligorio F, Di Cosimo S, Verderio P, Ciniselli CM, Pizzamiglio S, Castagnoli L, Dugo M, Galbardi B, Salgado R, Loi S, **Michiels S**, Triulzi T, Tagliabue E, El-Abed S, Izquierdo M, de Azambuja E, Nuciforo P, Huober J, Moscetti L, Janni W, Coccia-Portugal MA, Corsetto PA, Belfiore A, Lorenzini D, Daidone MG, Vingiani A, Gianni L, Pupa SM, Bianchini G, Pruneri G, Vernieri C.
Predictive role of CD36 expression in HER2-positive breast cancer patients receiving neoadjuvant trastuzumab. *Journal of the National Cancer Institute*. 2022 Dec 8;114(12):1720-1727. doi: 10.1093/jnci/djac126. PMID : 35789270

76. Barlesi F, Tomasini P, **Karimi M**, **Michiels S**, Raimbourg J, Daniel C, Janicot H, Madroszyk A, Audigier-Valette C, Quoix E, Mazieres J, Moro-Sibilot D, Dansin E, Molinier O, Morel H, Pichon E, Cortot A, Otto J, Chomy FO, Souquet PJ, Cloarec N, Giroux Leprieur E, Bieche I, Lacroix L, Boyault S, Attignon V, Soubeyran I, Morel A, Tran-Dien A, Jacquet A, Dall'Olio FG, Jimenez M, Soria JC, Besse B.
Comprehensive genome profiling in patients with metastatic non-small cell lung cancer: the precision medicine phase 2 randomized SAFIR02-Lung trial.
Clinical Cancer Research. 2022 Sep 15;28(18):4018-4026.
doi: 10.1158/1078-0432.CCR-22-0371. PMID : 35802649
77. Baker JL, Di Meglio A, Gbenou AS, El Mouhebb M, Iyengar NM, **Michiels S**, Cottu P, Lerebours F, Coutant C, Lesur A, Tredan O, Vanlemmens L, Jouannaud C, Hrab I, Everhard S, Martin AL, Arveux P, Fabrice A, Vaz-Luis I, Jones LW.
Association between physical activity and neoadjuvant chemotherapy completion and pathologic complete response in primary breast cancer: the CANTO study.
British journal of cancer. 2022 Sep;127(5):886-891.
doi: 10.1038/s41416-022-01870-y. Epub 2022 Jun 17. PMID : 35715631
78. Nguyen Van Long F, Lardy-Cleaud A, Carène D, **Rossoni C**, Catez F, Rollet P, Pion N, Monchiet D, Dolbeau A, Martin M, Simioni V, Bray S, Le Beherec D, Mosele F, Bouakka I, Colombe-Vermorel A, Odeyer L, Diot A, Jordan LB, Thompson AM, Jamen F, Dubois T, Chabaud S, **Michiels S**, Treilleux I, Bourdon JC, Pérol D, Puisieux A, André F, Diaz JJ, Marcel V.
Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer. BioMed Central cancer.
2022 May 11;22(1):526. doi: 10.1186/s12885-022-09552-x. PMID : 35545761
79. Martin E, Di Meglio A, Menvielle G, Arvis J, Bourmaud A, **Michiels S**, Pistilli B, Vaz-Luis I, Dumas A.
Informing the development of multidisciplinary interventions to help breast cancer patients return to work: a qualitative study. Supportive care in cancer.
2022 Oct;30(10):8287-8299. doi: 10.1007/s00520-022-07262-5. Epub 2022 Jul 12.
PMID : 35819520
80. Di Meglio A, Havas J, Soldato D, Presti D, Martin E, Pistilli B, Menvielle G, Dumas A, Charles C, Everhard S, Martin AL, Coutant C, Tarpin C, Vanlemmens L, Levy C, Rigal O, Delaloge S, Lin NU, Ganz PA, Partridge AH, André F, **Michiels S**, Vaz-Luis I.
Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care.
Journal of clinical oncology. 2022 Apr 1;40(10):1111-1123.
doi: 10.1200/JCO.21.01252. Epub 2022 Jan 21. PMID : 35061509

81. Conversano A, Abbaci M, **Karimi M**, Mathieu MC, de Leeuw F, **Michiels S**, Laplace-Builhé C, Mazouni C.
Axillary reverse mapping using near-infrared fluorescence imaging in invasive breast cancer (ARMONIC study). *European Journal of Surgical Oncology*. 2022 Dec;48(12):2393-2400. doi: 10.1016/j.ejso.2022.07.004. Epub 2022 Jul 8. PMID : 35840448
82. de Jong VMT, Wang Y, Ter Hoeve ND, Opdam M, Stathonikos N, Józwiak K, Hauptmann M, Cornelissen S, Vreuls W, Rosenberg EH, Koop EA, Varga Z, van Deurzen CHM, Mooyaart AL, Córdoba A, Groen EJ, Bart J, Willems SM, Zolota V, Wesseling J, Sapino A, Chmielik E, Ryska A, Broeks A, Voogd AC, Loi S, **Michiels S**, Sonke GS, van der Wall E, Siesling S, van Diest PJ, Schmidt MK, Kok M, Dackus GMHE, Salgado R, Linn SC.
Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy. 2022 Jul 20;40(21):2361-2374. doi: 10.1200/JCO.21.01536. Epub 2022 Mar 30. PMID: 35353548
83. Mogenet A, Barlesi F, Besse B, **Michiels S**, **Karimi M**, Tran-Dien A, Girard N, Mazieres J, Audigier-Valette C, Locatelli-Sanchez M, Kamal M, Gestraud P, Hamza A, Jacquet A, Jimenez M, Yara S, Greillier L, Bertucci F, Planchard D, Soria JC, Bieche I, Tomasini P.
Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome. *Lung Cancer*. 2022 Jul;169:31-39. doi: 10.1016/j.lungcan.2022.05.004. Epub 2022 May 18. PMID : 35609409
84. **Rincourt SL**, **Michiels S**, **Drubay D**.
Complex Disease Individual Molecular Characterization Using Infinite Sparse Graphical Independent Component Analysis. *Cancer Informatics*. 2022 Jul 15;21:11769351221105776. doi: 10.1177/11769351221105776. eCollection 2022. PMID : 35860346
85. Pautier P, Italiano A, Piperno-Neumann S, Chevreau C, Penel N, Firmin N, Boudou-Rouquette P, Bertucci F, Balleyguier C, Lebrun-Ly V, Ray-Coquard I, Kalbacher E, **Bardet A**, Bompas E, Collard O, Isambert N, Guillemet C, Rios M, **Archambaud B**, Duffaud F; French Sarcoma Group.
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial. *The Lancet Oncology*. 2022 Aug;23(8):1044-1054. doi: 10.1016/S1470-2045(22)00380-1. Epub 2022 Jul 11. PMID : 35835135

86. Vasseur D, Sassi H, **Bayle A**, Tagliamento M, Besse B, Marzac C, Arbab A, Auger N, Cotteret S, Aldea M, Blanc-Durand F, Géraud A, Gazzah A, Lorient Y, Hollebecq A, Martín-Romano P, Ngo-Camus M, Nicotra C, Ponce S, Sakkal M, Caron O, Smolenski C, Micol JB, Italiano A, Rouleau E, Lacroix L.
Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test. *Cells*. 2022 Jun 11;11(12):1901.
doi: 10.3390/cells11121901. PMID: 35741030
87. Espenel S, Chargari C, **Blanchard P**, Bockel S, Morel D, Rivera S, Levy A, Deutsch E. Practice changing data and emerging concepts from recent radiation therapy randomised clinical trials. *European Journal of Cancer*.
2022 Aug;171:242-258. doi: 10.1016/j.ejca.2022.04.038. Epub 2022 Jun 29.
PMID : 35779346
88. De Ioris MA, Fabozzi F, Lodi M, Vitali G, De Pasquale MD, Del Baldo G, **Abbas R**, Agolini E, Crocoli A, Iacusso C, Milano GM, Serra A, Mastronuzzi A.
The Fight Just Born-Neonatal Cancer: Rare Occurrence with a Favorable Outcome but Challenging Management. *Cancers*. 2022 Apr 29;14(9):2244.
doi: 10.3390/cancers14092244. PMID : 35565372
89. Cerbone L, Nunno VD, Carril Ajuria L, Alves Costa Silva C, Colomba E, Guida A, **Salviat F**, Hirsch L, Benchimol-Zouari A, Flippot R, Escudier B, Albiges L. Activity of Systemic Treatments After Cabozantinib Failure in Advanced Metastatic Renal Cell Carcinoma. *Clinical Genitourinary Cancer*.
2022 Feb;20(1):80-87. doi: 10.1016/j.clgc.2021.09.001. Epub 2021 Sep 24.
PMID: 34688544
90. Favier A, Boinon D, **Salviat F**, Mazouni C, De Korvin B, Tunon C, Salomon AV, Doutriaux-Dumoulin I, Vaysse C, Marchal F, Boulanger L, Chabbert-Buffet N, Zilberman S, Coutant C, Espié M, Cortet M, BouSSION V, Cohen M, Fermeaux V, Mathelin C, **Michiels S**, Delalogue S, Uzan C, Charles C.
[Surgery or not on an atypical breast lesion? Taking anxiety into account in shared decision support from a prospective cohort of 300 patients]. [Article in French]. *Gynécologie, Obstétrique, Fertilité & Sénologie*.
2022 Feb;50(2):142-150. doi: 10.1016/j.gofs.2021.09.010. Epub 2021 Sep 22.
PMID : 34562643

91. Chen J, Facchinetti F, Braye F, Yurchenko AA, Bigot L, Ponce S, Planchard D, Gazzah A, Nikolaev S, **Michiels S**, Vasseur D, Lacroix L, Tselikas L, Nobre C, Olaussen KA, Andre F, Scoazec JY, Barlesi F, Soria JC, Loriot Y, Besse B, Friboulet L. Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients. *Annals of oncology*. 2022 Apr;33(4):434-444. doi: 10.1016/j.annonc.2022.01.004. Epub 2022 Jan 21. PMID : 35066105
92. Kammer M, Dunkler D, **Michiels S**, Heinze G. Evaluating methods for Lasso selective inference in biomedical research: a comparative simulation study. *BMC medical research methodology*. 2022 Jul 26;22(1):206. doi: 10.1186/s12874-022-01681-y. PMID : 35883041
93. Remon J, **Lacas B**, Herbst R, Reck M, Garon EB, Scagliotti GV, Ramlau R, Hanna N, Vansteenkiste J, Yoh K, Groen HJM, Heymach JV, Mandrekar SJ, Okamoto I, Neal JW, Heist RS, Planchard D, **Pignon JP**, Besse B; ANSELMA collaborative group. ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. *European Journal of Cancer*. 2022 May;166:112-125. doi: 10.1016/j.ejca.2022.02.002. Epub 2022 Mar 11. PMID : 35286903
94. Witlox WJA, Ramaekers BLT, **Lacas B**, Le Pechoux C, Sun A, Wang SY, Hu C, Redman M, van der Noort V, Li N, Guckenberger M, van Tinteren H, Hendriks LEL, Groen HJM, Joore MA, De Ruyscher DKM. Cost-effectiveness of prophylactic cranial irradiation in stage III non-small cell lung cancer. *Radiotherapy and oncology*. 2022 May;170:95-101. doi: 10.1016/j.radonc.2022.02.036. Epub 2022 Mar 5. PMID : 35259416
95. Saghatchian M, **Lacas B**, Charles C, Ghouadni A, Clain GT, Boinon D, Delaloge S, Vaz-Luis I, Dauchy S, Amiel P. BEAUTY and the breast: is adjuvant chemotherapy the right time for a beauty boost? Lessons learned from a large randomized controlled trial. *Quality of life research*. 2022 Mar;31(3):723-732. doi: 10.1007/s11136-021-02947-6. Epub 2021 Jul 29. PMID: 34324138

96. Goubet AG, Lordello L, Alves Costa Silva C, Peguillet I, Gazzano M, Mbogning-Fonkou MD, Thelemaque C, Lebacle C, Thibault C, Audenet F, Pignot G, Gravis G, Helissey C, Campedel L, Roupret M, Xylinas E, Ouzaid I, Dubuisson A, Mazzenga M, Flament C, Ly P, Marty V, Signolle N, Sauvat A, Sbarrato T, Filahi M, Davin C, Haddad G, Bou Khalil J, Bleriot C, Danlos FX, Dunsmore G, Mulder K, Silvin A, Raoult T, **Archambaud B**, **Belhechmi S**, Gomperts Boneca I, Cayet N, Moya-Nilges M, Mallet A, Daillere R, Rouleau E, Radulescu C, Allory Y, Fieschi J, Rouanne M, Ginhoux F, **Le Teuff G**, Derosa L, Marabelle A, VAN Dorp J, VAN Dijk N, van der Heijden MS, Besse B, Andre F, Merad M, Kroemer G, Scoazec JY, Zitvogel L, Lorient Y.
Escherichia coli-specific CXCL13-producing TFH are associated with clinical efficacy of neoadjuvant PD-1 blockade against muscle-invasive bladder cancer. *Cancer Discovery*. 2022 Oct 5;12(10):2280-2307.
doi: 10.1158/2159-8290.CD-22-0201. PMID : 35929803
97. **Hill C**, Barouki R, Audouze K, Coumoul X.
[Endocrine disruptors : a discussed risk] [Article in French].
La Revue du Praticien. 2022 Jan;72(1):13-16. PMID: 35258248
98. **Blanchard P**, Vickers AJ.
Prostatectomy in Patients with Oligometastatic Hormone-sensitive Prostate Cancer? Not Yet. *European Urology Oncology*.
2022 Oct;5(5):526-527. doi: 10.1016/j.euo.2022.07.005. Epub 2022 Aug 5.
PMID : 35934624
99. Biau J, Pointreau Y, **Blanchard P**, Khamphan C, Giraud P, Lapeyre M, Maingon P.
[Erratum to "Radiotherapy for laryngeal cancers" [*Cancer Radiother*. 26 (2022) 206-12]]. [Article in French]. *Cancer Radiothérapie*.
2022 Sep;26(5):754. doi: 10.1016/j.canrad.2022.04.001. Epub 2022 Aug 5.
PMID : 35934620
100. **Faron M**, Lamartina L, Hescot S, Moog S, Deschamps F, Roux C, Libe R, Durand-Labrunie J, Al Ghuzlan A, Hadoux J, Baudin E.
New endpoints in adrenocortical carcinoma studies: a mini review. *Endocrine*.
2022 Sep;77(3):419-424. doi: 10.1007/s12020-022-03128-2. Epub 2022 Jul 23.
PMID : 35869971
101. Siebert M, Lucas N, Gelli M, Sourrouille I, Benhaïm L, **Faron M**, Micol JB, Ducreux M, Stoclin A, Honoré C.
Acute Abdominal Complications in Deeply Neutropenic Onco-Hematology Patients: A Retrospective Series of 105 Cases. *World Journal of Surgery*.
2022 Oct;46(10):2389-2398. doi: 10.1007/s00268-022-06653-3.
Epub 2022 Jul 11. PMID : 35816234

102. Gaujoux S, Martin GL, Mirallié E, Regenet N, Le Bras M, Pattou F, Carnaille B, Cardot-Bauters C, Groussin L, **Faron M**, Chanson P, Najah H, Tabarin A, Sauvanet A, Ruzsniwski P, Lifante JC, Walter T, Carrère N, Caron P, Deguelte S, Delemer B, Binquet C, Jannot AS, Goudet P.
Life expectancy and likelihood of surgery in multiple endocrine neoplasia type 1: AFCE and GTE cohort study. *The British Journal of Surgery*. 2022 Aug 16;109(9):872-879. doi: 10.1093/bjs/znac006. PMID : 35833229
103. Hadoux J, Walter T, Kanaan C, Hescot S, Hautefeuille V, Perrier M, Tauveron I, Laboureau S, Do Cao C, Pétorin C, Blanchet O, **Faron M**, Leteurre E, Rousselet MC, Joubert Zakeyh J, Marchal A, Chatelain D, Beaulaton C, Hervieu V, Lombard-Bohas C, Ducreux M, Scoazec JY, Baudin E.
Second-line treatment and prognostic factors in neuroendocrine carcinoma. *Endocrine-related Cancer*. 2022 Aug 17;29(10):569-580.
doi: 10.1530/ERC-22-0102. Print 2022 Oct 1. PMID : 35920609
104. Ribeiro AI, Fraga S, Severo M, Kelly-Irving M, Delpierre C, Stringhini S, Kivimaki M, Joost S, Guessous I, Severi G, Giles G, Sacerdote C, Vineis P, Barros H; **LIFEPATH Consortium**. Association of neighbourhood disadvantage and individual socioeconomic position with all-cause mortality: a longitudinal multicohort analysis. *Lancet Public Health*. 2022 May;7(5):e447-e457.
doi: 10.1016/S2468-2667(22)00036-6. PMID : 35487230
105. Régis C, **Le Deley MC**, Bogart E, Leguillette C, Boulanger L, Chauvet MP, Viard R, Thery J, Bosc R, Delmaire C.
Functional Cerebral MRI Evaluation of Integration of Breast Reconstruction into the Body Schema. *Annals of surgical oncology*. 2022 Apr;29(4):2652-2661.
doi: 10.1245/s10434-021-11048-0. Epub 2021 Nov 27.
PMID : 34839425
106. Rodriguez D, Calmon R, Aliaga ES, Warren D, Warmuth-Metz M, Jones C, Mackay A, Varlet P, **Le Deley MC**, Hargrave D, Cañete A, Massimino M, Azizi AA, Saran F, Zahlmann G, Garcia J, Vassal G, Grill J, Peet A, Dineen RA, Morgan PS, Jaspan T.
MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial. *Radiology*. 2022 Jul;304(1):174-182.
doi: 10.1148/radiol.211464. Epub 2022 Apr 12. PMID : 35412366
107. Bridoux M, **Le Deley MC**, Bertrand N, Simon N, Sylla D, Mirabel X, Turpin A.
Effects of Proton Pump Inhibitors Intake During Chemoradiotherapy for Rectal Cancer: a Retrospective Cohort Study. *Journal of Gastrointestinal Cancer*. 2022 May 14. doi: 10.1007/s12029-022-00825-z. Online ahead of print.
PMID : 35568776

108. Hautecloque-Rayz S, Albert-Thananayagam M, Martignene N, **Le Deley MC**, Carbonnelle G, Penel N, Carnot A.
Long-Term Outcomes and Prognostic Factors of Patients with Metastatic Solid Tumors Admitted to the Intensive Care Unit. *Oncology*. 2022;100(3):173-181.
doi: 10.1159/000520097. Epub 2022 Jan 20. PMID : 35051928
109. Mailliez A, Pigny P, Bogart E, Keller L, D'Orazio E, Vanseymortier M, **Le Deley MC**, Decanter C.
Is ovarian recovery after chemotherapy in young patients with early breast cancer influenced by controlled ovarian hyperstimulation for fertility preservation or tumor characteristics? Results of a prospective study in 126 patients.
International Journal of Cancer. 2022 Jun 1;150(11):1850-1860.
doi: 10.1002/ijc.33933. Epub 2022 Feb 7. PMID : 35038360
110. Colomba E, Alves Costa Silva C, **Le Teuff G**, Elmawieh J, Afonso D, Benchimol-Zouari A, Guida A, Derosa L, Flippot R, Raynard B, Escudier B, Bidault F, Albiges L. Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma. *Journal of Cachexia, Sarcopenia and Muscle*.
2022 Oct;13(5):2405-2416. doi: 10.1002/jcsm.13021. Epub 2022 Jul 28.
PMID : 35903892
111. Del Baldo G, **Abbas R**, De Ioris MA, Di Ruscio V, Alessi I, Miele E, Mastronuzzi A, Milano GM.
The Prognostic Role of the C-Reactive Protein and Serum Lactate Dehydrogenase in a Pediatric Series of Bone Ewing Sarcoma. *Cancers*.
2022 Jun 22;14(13):3064. doi: 10.3390/cancers14133064. PMID : 35804835
112. Abbaci M, Casiraghi O, Vergez S, **Maillard A**, Lakhdar AB, De Leeuw F, Crestani S, Ngo C, Koscielny S, Ferchiou M, Assouly N, Temam S, Laplace-Builhé C, Breuskin I.
Diagnostic accuracy of in vivo early tumor imaging from probe-based confocal laser endomicroscopy versus histologic examination in head and neck squamous cell carcinoma. *Clinical oral investigations*. 2022 Feb;26(2):1823-1833.
doi: 10.1007/s00784-021-04156-4. Epub 2021 Oct 12. PMID : 34636941

113. Wysocki O, Zhou C, Rogado J, Huddar P, Shotton R, Tivey A, Albiges L, Angelakas A, Arnold D, Aung T, Banfill K, Baxter M, Barlesi F, **Bayle A**, Besse B, Bhogal T, Boyce H, Britton F, Calles A, Castelo-Branco L, Copson E, Croitoru A, Dani SS, Dickens E, Eastlake L, Fitzpatrick P, **Foulon S**, Frederiksen H, Ganatra S, Gennatas S, Glenthøj A, Gomes F, Graham DM, Hague C, Harrington K, Harrison M, Horsley L, Hoskins R, Hudson Z, Jakobsen LH, Joharatnam-Hogan N, Khan S, Khan UT, Khan K, Lewis A, Massard C, Maynard A, McKenzie H, Michielin O, Mosenthal AC, Obispo B, Palmieri C, Patel R, Pentheroudakis G, Peters S, Rieger-Christ K, Robinson T, Romano E, Rowe M, Sekacheva M, Sheehan R, Stockdale A, Thomas A, Turtle L, Viñal D, Weaver J, Williams S, Wilson C, Dive C, Landers D, Cooksley T, Freitas A, Armstrong AC, Lee RJ, On Behalf Of The Esmo Co-Care. An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves. *Cancers*. 2022 Aug 16;14(16):3931. doi: 10.3390/cancers14163931. PMID : 36010932
114. **Benhamou S**, Fournier E, Puppa G, McKee T, Ris F, Rubbia-Brandt L, Viassolo V, Zilli T, Zlobec I, Chappuis PO, Rapiti E. Cohort profile: population-based cohorts of patients with colorectal cancer and of their relatives in Geneva, Switzerland. *BMJ Open*. 2022 Aug 25;12(8):e063914. doi: 10.1136/bmjopen-2022-063914. PMID : 36008070
115. Chang D, **Blanchard P**, Siva Shankar. The Deep Blue of Prostate Cancer Metastasis Evolution: The LEVIATHAN Pooled Analysis. *European Urology*. 2022 Nov;82(5):499-500. doi: 10.1016/j.eururo.2022.08.006. Epub 2022 Aug 20. PMID : 35995643
116. Pierre T, Selhane F, Zareski E, Garcia C, Fizazi K, Loriot Y, Patrikidou A, Naoun N, Bernard-Tessier A, Baumert H, Lebacle C, **Blanchard P**, Rocher L, Balleyguier C. The Role of CT in the Staging and Follow-Up of Testicular Tumors: Baseline, Recurrence and Pitfalls. *Cancers*. 2022 Aug 17;14(16):3965. doi: 10.3390/cancers14163965. PMID : 36010958
117. Modesto A, Graff Cailleaud P, **Blanchard P**, Boisselier P, Pointreau Y. [Challenges and limits of therapeutic de-escalation for papillomavirus-related oropharyngeal cancer]. [Article in French]. *Cancer Radiothérapie*. 2022 Oct;26(6-7):921-924. doi: 10.1016/j.canrad.2022.06.018. Epub 2022 Aug 24. PMID : 36030192

118. Vilotte F, Pasquier D, **Blanchard P**, Supiot S, Khalifa J, Schick U, Lacornerie T, Vieillevigne L, Marre D, Chapet O, Latorzeff I, Magne N, Meyer E, Cao K, Belkacemi Y, Bibault JE, Berge-Lefranc M, Faivre JC, Gnep K, Guimas V, Hasbini A, Langrand-Escure J, Hennequin C, Graff P.
Recommendations for stereotactic body radiation therapy for spine and non-spine bone metastases. A GETUG (French society of urological radiation oncologists) consensus using a national two-round modified Delphi survey.
Clinical and translational radiation oncology. 2022 Aug 8;37:33-40.
doi: 10.1016/j.ctro.2022.08.006. eCollection 2022 Nov. PMID : 36052019
119. Hescot S, Al Ghuzlan A, Henry T, Sheikh Alard H, Lamartina L, **Borget I**, Hadoux J, Baudin E, Dupuy C, Nikitski AV, Nikiforov YE, Schlumberger M, Nikiforova MN, Leboulleux S.
Prognostic of recurrence and survival in poorly differentiated thyroid cancer.
Endocrine-related Cancer. 2022 Sep 30;29(11):625-634. doi: 10.1530/ERC-22-0151. Print 2022 Nov 1. PMID : 36040800
120. Palmer S, **Borget I**, Friede T, Husereau D, Karnon J, Kearns B, Medin E, Peterse EFP, Klijn SL, Verburg-Baltussen EJM, Fenwick E, Borrill J.
A Guide to Selecting Flexible Survival Models to Inform Economic Evaluations of Cancer Immunotherapies. Value in Health.
2022 Aug 13;S1098-3015(22)02105-2. doi: 10.1016/j.jval.2022.07.009.
Online ahead of print. PMID : 35970706
121. Lamy C, Tissot H, **Faron M**, Baudin E, Lamartina L, Pradon C, Al Ghuzlan A, Leboulleux S, Perfettini JL, Paci A, Hadoux J, Broutin S.
Succinate: a serum biomarker of SDHB mutated paragangliomas and pheochromocytomas. The Journal of Clinical Endocrinology and Metabolism.
2022 Sep 28;107(10):2801-2810. doi: 10.1210/clinem/dgac474. PMID : 35948272
122. Watson S, Verret B, Ropert S, Adam J, Bahleda R, Briand S, Cavalcanti A, Chamseddine AN, Court C, Fadel E, **Faron M**, Haddag-Miliani L, Henon C, Pechoux CL, Levy A, Mercier O, Ngo C, Honoré C, Cesne AL, Mir O.
Single-agent gemcitabine in patients with advanced, pre-treated angiosarcoma: A multicenter, retrospective study. Cancer Medicine. 2022 Aug 15.
doi: 10.1002/cam4.5147. Online ahead of print. PMID : 35971325
123. Roquette I, Bogart E, Lacornerie T, Ningarhari M, Bibault JE, **Le Deley MC**, Lartigau EF, Pasquier D, Mirabel X.
Stereotactic Body Radiation Therapy for the Management of Hepatocellular Carcinoma: Efficacy and Safety. Cancers. 2022 Aug 11;14(16):3892.
doi: 10.3390/cancers14163892. PMID : 36010885

124. Nauwelaers I, Laudus N, Peeters D, Acs B, Denkert C, **Michiels S**, Horlings H, Siziopikou KP, Ely S, Zardavas D, Mustimbo R, Bartlett J, Floris G, Hartman J, van Deurzen CHM, Ceusters D, Dequeker E, Salgado R.
External Quality Assessment 2.0: The Importance of a Standardized Implementation of TILs for Daily and Trial Practices. *Cancers*.
2022 Aug 2;14(15):3762. doi: 10.3390/cancers14153762. PMID : 35954426
125. **Pagès A**, Costa N, Mounié M, Cestac P, De Souto Barreto P, Rolland Y, Vellas B, Molinier L, Juillard-Condat B; MAPT/DSA Group.
Healthcare Costs Associated with Potentially Inappropriate Medication Prescribing Detected by Computer Algorithm Among Older Patients. *Drugs Aging*.
2022 May;39(5):367-375. doi: 10.1007/s40266-022-00938-x.
Epub 2022 May 24. PMID : 35606646
126. **Deneche I**, Touzani R, Bouhnik AD, Rey D, Bendiane MK, Chirpaz E.
Factors associated with mammography screening among Reunionese women : a cross-sectional study. *Revue d'Epidémiologie et de Santé Publique*.
2022 Jun;70(3):117-122. doi: 10.1016/j.respe.2022.03.122. Epub 2022 Apr 28.
PMID: 35491336
127. Di Meglio A, Charles C, Martin E, Havas J, Gbenou A, Flaysakier JD, Martin AL, Everhard S, Laas E, Chopin N, Vanlemmens L, Jouannaud C, Levy C, Rigal O, Fournier M, Soulie P, Scotte F, Pistilli B, Dumas A, Menvielle G, André F, **Michiels S**, Dauchy S, Vaz-Luis I.
Uptake of Recommendations for Posttreatment Cancer-Related Fatigue Among Breast Cancer Survivors.
Journal of the National Comprehensive Cancer Network. 2022 Feb 7;20(13). doi: 10.6004/jnccn.2021.7051. PMID: 35130491
128. Pautier P, **Tanguy ML**, **Archambaud B**.
Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma - Authors' reply. *The Lancet Oncology*. 2022 Oct;23(10):e445.
doi: 10.1016/S1470-2045(22)00563-0. PMID: 36174626
129. **Bayle A**, Peyraud F, Belcaid L, Brunet M, Aldea M, Clodion R, Dubos P, Vasseur D, Nicotra C, Geraud A, Sakkal M, Cerbone L, Blanc-Durand F, Mosele F, Romano PM, Camus MN, Soubeyran I, Khalifa E, Alame M, Blouin L, Dinart D, Bellera C, Hollebecque A, Ponce S, Loriot Y, Besse B, Lacroix L, Rouleau E, Barlesi F, Andre F, Italiano A.
Liquid versus tissue biopsy for detecting actionable alterations according to ESCAT in patients with advanced cancer: A study from the French National Center for Precision Medicine (PRISM). *Annals of Oncology*.
2022 Dec;33(12):1328-1331. doi: 10.1016/j.annonc.2022.08.089.
Epub 2022 Sep 17. PMID: 36122799

130. Ng WT, But B, Wong CHL, Choi CW, Chua MLK, **Blanchard P**, Lee AWM. Particle beam therapy for nasopharyngeal cancer: A systematic review and meta-analysis. *Clinical and Translational Radiation Oncology*. 2022 Aug 23;37:41-56. doi: 10.1016/j.ctro.2022.08.011. eCollection 2022 Nov. PMID: 36065359
131. Gorphe P, **Blanchard P**, Garcia GCTE, Classe M, Even C, Temam S, Breuskin I. 2011-2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France. *BMC Cancer*. 2022 Sep 20;22(1):1000. doi: 10.1186/s12885-022-10091-8. PMID: 36127667
132. Zilli T, Achard V, Dal Pra A, Schmidt Hegemann N, Alicja Jereczek-Fossa B, Lancia A, Ingrosso G, Alongi F, Aluwini S, Arcangeli S, **Blanchard P**, Conde Moreno A, Couñago F, Créhange G, Dirix P, Gomez Iturriaga A, Guckenberger M, Pasquier D, Sargos P, Scorsetti M, Supiot S, Tree AC, Zapatero A, Le Guevelou J, Ost P, Belka C. Recommendations for Radiation Therapy in Oligometastatic Prostate Cancer: an ESTRO-ACROP Delphi consensus. *Radiotherapy and oncology*. 2022 Nov;176:199-207. doi: 10.1016/j.radonc.2022.10.005. Epub 2022 Oct 10. PMID: 36228761
133. Palafox M, Monserrat L, Bellet M, Villacampa G, Gonzalez-Perez A, Oliveira M, Brasó-Maristany F, **Ibrahimi N**, Kannan S, Mina L, Herrera-Abreu MT, Òdena A, Sánchez-Guixé M, Capelán M, Azaro A, Bruna A, Rodríguez O, Guzmán M, Grueso J, Viaplana C, Hernández J, Su F, Lin K, Clarke RB, Caldas C, Arribas J, **Michiels S**, García-Sanz A, Turner NC, Prat A, Nuciforo P, Dienstmann R, Verma CS, Lopez-Bigas N, Scaltriti M, Arnedos M, Saura C, Serra V. High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer. *Nature communications*. 2022 Sep 7;13(1):5258. doi: 10.1038/s41467-022-32828-6. PMID: 36071033
134. Coudert V, Penel N, **Le Deley MC**, Forestier A. [Expertise for management of immune-related adverse events in cancer therapy: Mapping of French practicing]. *Bulletin du Cancer*. 2022 Nov;109(11):1217-1226. doi: 10.1016/j.bulcan.2022.07.005. Epub 2022 Sep 7. PMID : 36088179
135. Debaudringhien M, Blay JY, Bimbai AM, Bonvalot S, Italiano A, Rousset-Jablonski C, Corradini N, Piperno-Neumann S, Chevreau C, Kurtz JE, Guillemet C, Bompas E, Collard O, Salas S, Le Cesne A, Orbach D, Thery J, **Le Deley MC**, Mir O, Penel N. Association between recent pregnancy or hormonal contraceptive exposure and outcome of desmoid-type fibromatosis. *ESMO Open*. 2022 Oct;7(5):100578. doi: 10.1016/j.esmoop.2022.100578. Epub 2022 Sep 16. PMID : 36116422

136. Brogaard N, Abdul-Ghani R, **Bayle A**, Henderson N, Bréant A, Steuten, L. Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies. OHE Consulting Report. January 2022.
137. Le Corroller AG, **Bonastre J**.
Patient-reported measures: how useful in health economics?
The European Journal of Health Economics. 2022 Nov 8.
doi: 10.1007/s10198-022-01524-z. Online ahead of print. PMID : 36346476
138. Rassy E, **Bardet A**, Bougacha O, Gantzer L, Lekens B, Delalogue S, André F, **Michiels S**, Pistilli B.
Association of Adherence to Endocrine Therapy Among Patients With Breast Cancer and Potential Drug-Drug Interactions. JAMA network open.
2022 Dec 1;5(12):e2244849. doi: 10.1001/jamanetworkopen.2022.44849.
PMID: 36459136
139. **Kandel M**, **Bardet A**, Dalle S, Allayous C, Mortier L, Guillot B, Dutriaux C, Leccia MT, Dalac S, Montaudie H, Saiag P, Legoupil D, Brunet-Possenti F, Arnault JP, Quatrebarbes J, Beylot-Barry M, Maubec E, Lesimple T, Aubin F, Grob JJ, Granel-Brocard F, Stoebner PE, Dupuy A, Dreno B, **Michiels S**, Lebbe C, **Borget I**.
Cost-Effectiveness Analysis of Sequential Treatment Strategies for Advanced Melanoma in Real Life in France. Current oncology.
2022 Nov 27;29(12):9255-9270. doi: 10.3390/curroncol29120725. PMID: 36547139
140. Barraud S, Tougeron D, Villeneuve L, Eveno C, **Bayle A**, Parc Y, Pocard M, André T, Cohen R.
Immune checkpoint inhibitors for patients with isolated peritoneal carcinomatosis from dMMR/MSI-H colorectal cancer, a BIG-RENAPE collaboration.
Digestive and liver disease. 2022 Oct 17;S1590-8658(22)00726-5.
doi: 10.1016/j.dld.2022.09.015. Online ahead of print. PMID: 36266207
141. **Hilmi M**, Naoun N, Boilève A, Géraud A, **Bayle A**, Pagès A, Aupomerol M, Rouanne M, Madec FX, Pommeret F, Massard C, Baldini C, Scotté F, Champiat S.
Evaluation of supportive care needs, sexuality and quality of life in phase 1 trials: a prospective monocentric study. Supportive care in cancer.
2022 Dec;30(12):9841-9849. doi: 10.1007/s00520-022-07407-6.
Epub 2022 Oct 22. PMID: 36271944

142. Aldea M, Belkhir R, Colomba E, **Blanchard P**, Danlos FX, Botticella A, Terlizzi M, Deutsch E, Le Péchoux C, Planchard D, Michot JM, Besse B, Levy A. Immune-related arthritis following pelvic radiation therapy in a patient with lung cancer receiving long-term immune checkpoint blocker treatment: Case report. *Frontiers in immunology*. 2022 Oct 24;13:920130. doi: 10.3389/fimmu.2022.920130. eCollection 2022. PMID: 36353627
143. de Pouvourville G, Armoiry X, Lavorel A, Bilbault P, Maugendre P, Bensimon L, Beziz D, Blin P, **Borget I**, Bouée S, Collignon C, Dervaux B, Durand-Zaleski I, Julien M, de Léotoing L, Majed L, Martelli N, Séjourné T, Viprey M. Données et preuves en vie réelle dans l'évaluation des technologies de santé : dans quels cas sont-elles complémentaires, substitutives, ou les seules sources de données par rapport aux essais cliniques ? [Article in French] *Thérapie*. 2022 Oct 29;S0040-5957(22)00236-0. doi: 10.1016/j.therap.2022.10.067. Online ahead of print. PMID: 36446648
144. Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, **Blanchard P**, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ngozi Ekeke O, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Alicja Jereczek-Fossa B, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khaulil RB, Klotz L, Kramer G, Leibowitz R, Logothetis CJ, Mahal BA, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Pablo Sade J, Sartor OA, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale CL, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Zilli T, Omlin A. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. *European urology*. 2022 Dec 6;S0302-2838(22)02789-0. doi: 10.1016/j.eururo.2022.11.002. Online ahead of print. PMID: 36494221

145. Borson-Chazot, F, **Borget, I**, Mathonnet, M, Leenhardt, L.
SFE-AFCE-SFMN 2022 consensus on the management of thyroid nodules: Epidemiology and challenges in the management of thyroid nodules. *Annales d'endocrinologie (Paris)*. 2022 Dec;83(6):378-379. doi: 10.1016/j.ando.2022.10.003. Epub 2022 Oct 23. PMID: 36283463
146. de Pouvourville G, Armoiry X, Lavorel A, Bilbault P, Maugendre P, Bensimon L, Beziz D, Blin P, **Borget I**, Bouée S, Collignon C, Dervaux B, Durand-Zaleski I, Julien M, de Léotoing L, Majed L, Martelli N, Séjourné T, Viprey M.
Real-world data and evidence in health technology assessment: When are they complementary, substitutes, or the only sources of data compared to clinical trials? *Therapie*. 2022 Nov 12;S0040-5957(22)00240-2. doi: 10.1016/j.therap.2022.11.001. Online ahead of print. PMID: 36464522
147. Cordoba A, Durand B, Escande A, Taieb S, Amor MBH, **Le Deley MC**, Michel A, Le Tinier F, Hudry D, Martinez C, Leblanc E, Becourt S, Abdedaim C, Bresson L, Lartigau E, Mirabel X, Narducci F.
Prognostic impact of tumor size reduction assessed by magnetic resonance imaging after radiochemotherapy in patients with locally advanced cervical cancer. *Frontiers in oncology*. 2022 Dec 2;12:1046087. doi: 10.3389/fonc.2022.1046087. eCollection 2022. PMID: 36531006
148. Corvest V, Marec-Bérard P, Lervat C, Pacquement H, Toulmonde M, Gentet JC, Laurence V, Cleirec M, Mansuy L, Bompas E, Castex MP, Taque S, Filhon B, Tabone MD, Verité C, Entz-Werle N, Saumet L, Guimard G, Pondrom M, Chevreau C, Flandrin J, Duranteau L, Rousset-Jablonski C, Brugières L, Jimenez M, **Le Deley MC**, Gaspar N, Fresneau B.
Late toxicity comparison of alkylating-based maintenance regimen with cyclophosphamide (VAC) vs ifosfamide (VAI) in Ewing sarcoma survivors treated in the randomized clinical trial Euro-EWING99-R1 in France. *International Journal of Cancer*. 2022 Oct 17. doi: 10.1002/ijc.34326. Online ahead of print. PMID: 36250317
149. Colomba E, Alexandre J, **Le Teuff G**, Genestie C, Coupeuz D, Coquard IR, Brachet PE, de Percin S, Sajous C, Fabbro M, Delanoy N, Joly F, Frenel JS, Pautier P, Leary A.
Response to first line platinum-based chemotherapy in mismatch repair deficient (MMRd)/ microsatellite instability high (MSI-high) endometrial carcinoma. *Gynecologic oncology*. 2022 Dec 13;169:78-84. doi: 10.1016/j.ygyno.2022.11.029. Online ahead of print. PMID: 36521352

150. **Rincourt SL, Michiels S, Drubay D.**
A non-parametric Bayesian joint model for latent individual molecular profiles and survival in oncology. *Journal of Bioinformatics and Computational Biology*. 2022 Oct;20(5):2250022. doi: 10.1142/S0219720022500226.
Epub 2022 Oct 27. PMID: 36287465
151. Marmouset V, Decroocq J, Garciaz S, Etienne G, Belhabri A, Bertoli S, Gastaud L, Simand C, Chantepie S, Uzunov M, Genthon A, Berthon C, Chiche E, Dumas PY, Vargaftig J, Salmeron G, Lemasle E, Tavernier E, Delage J, Loirat M, Morineau N, Blanc-Durand F, Pautier P, Vergé V, Auger N, Thomas M, Stefani L, Lepelley M, Boyer T, Thepot S, Gourin MP, Bourquard P, Duchmann M, Morice PM, Michallet M, Adès L, Fenaux P, Récher C, Dombret H, **Pagès A**, Marzac C, Leary A, Micol JB; UNIHEM, French Network of Pharmacovigilance Centers, ALFA, FILO, and GFM.
Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience. *Clinical Cancer Research*. 2022 Dec 1;28(23):5211-5220.
doi: 10.1158/1078-0432.CCR-22-1622. PMID: 36201165
152. Fasse L, Roche N, Flahault C, Garrouste-Orgeas M, Ximenes M, **Pages A**, Evin A, Dauchy S, Scotte F, Le Provost JB, Blot F, Mateus C.
The APSY-SED study: protocol of an observational, longitudinal, mixed methods and multicenter study exploring the psychological adjustment of relatives and healthcare providers of patients with cancer with continuous deep sedation until death. *BMC palliative care*. 2022 Dec 5;21(1):217.
doi: 10.1186/s12904-022-01106-z. PMID: 36464684
153. Dercle L, Ammari S, **Roblin E**, Bigorgne A, Champiat S, Taihi L, Plaian A, Hans S, Lakiss S, Tselikas L, Rouanne M, Deutsch E, Schwartz LH, Gönen M, Flynn J, Massard C, Soria JC, Robert C, Marabelle A.
High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy. *European Journal of Cancer*. 2022 Dec;177:80-93. doi: 10.1016/j.ejca.2022.08.034. Epub 2022 Sep 30.
PMID: 36332438
154. Kfoury M, Najean M, Lappara A, Voisin AL, Champiat S, Michot JM, Laghouati S, Robert C, Besse B, Soria JC, Lambotte O, Massard C, Marabelle A, **Texier M**.
Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias.
Cancer Treatment Reviews. 2022 Aug 10;110:102452.
doi: 10.1016/j.ctrv.2022.102452. Online ahead of print. PMID : PMID: 35998515

155. Tran BT, Gelin A, Durand S, **Texier M**, Daste A, Toullec C, Benihoud K, Breuskin I, Gorphe P, Garic F, Brenner C, Le Tourneau C, Fayette J, Niki T, David M, Busson P, Even C.
Plasma galectins and metabolites in advanced head and neck carcinomas: evidence of distinct immune characteristics linked to hypopharyngeal tumors. *Oncoimmunology*. 2022 Dec 17;12(1):2150472.
doi: 10.1080/2162402X.2022.2150472. eCollection 2023. PMID: 36545254
156. Del Baldo G, Carai A, **Abbas R**, Cacchione A, Vinci M, Di Ruscio V, Colafati GS, Rossi S, Diomedei Camassei F, Maestro N, Temelso S, Pericoli G, De Billy E, Giovannoni I, Carboni A, Rinelli M, Agolini E, Mackay A, Jones C, Chiesa S, Balducci M, Locatelli F, Mastronuzzi A.
Targeted therapy for pediatric diffuse intrinsic pontine glioma: a single-center experience. *Therapeutic Advances in Medical Oncology*. 2022 Sep 6;14:17588359221113693. doi: 10.1177/17588359221113693.
eCollection 2022. PMID: 36090803
157. Rigault E, **Lacas B**, Glehen O, Smith D, Dupont-Bierre E, Guimbaud R, Malka D, Boige V, Fuerea A, **Pignon JP**, Ducreux M.
Intra-arterial hepatic bevacizumab and systemic chemotherapy in hepatic metastasis of colorectal cancer: A phase II multicentric trial in second-line treatment. *Cancer treatment and research communications*. 2022 Dec 16;34:100674. doi: 10.1016/j.ctarc.2022.100674. Online ahead of print. PMID: 36565566
158. Tonon F, Di Bella S, **Giudici F**, Zerbato V, Segat L, Koncan R, Misin A, Toffoli B, D'Agaro P, Luzzati R, Fabris B, Bernardi S.
Discriminatory Value of Adiponectin to Leptin Ratio for COVID-19 Pneumonia. *International Journal of Endocrinology*. 2022 Apr 26;2022:9908450.
doi: 10.1155/2022/9908450. eCollection 2022. PMID: 35529082
159. Bramuzzo M, Grazian F, Grigoletto V, Daidone A, Martelossi S, Mario F, Maurel E, Lega S, **Giudici F**, Di Leo G, Barbi E.
Dietary Beliefs in Children and Adolescents with Inflammatory Bowel Disease and their Parents. *Journal of Pediatric Gastroenterology and Nutrition*. 2022 Sep 1;75(3):e43-e48. doi: 10.1097/MPG.0000000000003527.
Epub 2022 Jun 16. PMID: 35706104
160. Antonaglia C, Vidoni G, Contardo L, **Giudici F**, Salton F, Ruaro B, Confalonieri M, Caneva M.
Low Arousal Threshold Estimation Predicts Failure of Mandibular Advancement Devices in Obstructive Sleep Apnea Syndrome. *Diagnostics (Basel)*. 2022 Oct 20;12(10):2548. doi: 10.3390/diagnostics12102548. PMID: 36292237

161. D'Angelo A, **Giudici F**, Chapman R, Darlow J, Kili H, Sobhani N, Cinelli M, Cappelletti MR, Strina C, Milani M, Generali D.
Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2- Breast Cancer Based on a Window of Opportunity Study.
Current issues in molecular biology. 2022 Sep 15;44(9):4255-4267.
doi: 10.3390/cimb44090292. PMID: 36135204
162. Paoletti X, **Michiels S**.
16e Conférence francophone d'Epidémiologie Clinique 29^e Journées des statisticiens des Centres de Lutte contre le Cancer Paris, 18-20 mai 2022.
Revue d'Epidémiologie et de Santé Publique. 2022 May;70:S61-S62.
10.1016/j.respe.2022.04.001
163. **Benkirane H**, Vakalopoulou M, Christodoulidis S, Garberis I-J, **Michiels S**, Cournède P-H.
Hyper-AdaC: Adaptive clustering-based hypergraph representation of whole slide images for survival analysis. Proceedings of the 2nd Machine Learning for Health symposium. Proceedings of Machine Learning Research. 2022 nov;193:405-418.
164. **Hill C**.
[A propos de l'article "Is early-onset cancer an emerging global epidemic ?" : pas de panique !]. Innovations & Thérapeutiques en Oncologie. 2022 sept-oct ; vol 8 – n°5.
doi : 10.1684/ito.2022.337
165. Farah L, Scher N, Zerbib M, Martelli N, **Borget I**, Guetta T, Bauduceau O, Tolédano A.
Analyse médicoéconomique de la radiothérapie stéréotaxique robotisée prostatique par comparaison à la prostatectomie totale robot-assistée en France.
Cancer Radiothérapie. doi : 10.1016/j.canrad.2020.08.021
166. Palafox M, Monserrat L, Bellet M, Villacampa G, Gonzalez-Perez A, Oliveira M, Brasó-Maristany F, **Ibrahimi N**, Kannan S, Mina L, Herrera-Abreu MT, Òdena A, Sánchez-Guixé M, Capelán M, Azaro A, Bruna A, Rodríguez O, Guzmán M, Grueso J, Viaplana C, Hernández J, Su F, Lin K, Clarke RB, Caldas C, Arribas J, **Michiels S**, García-Sanz A, Turner NC, Prat A, Nuciforo P, Dienstmann R, Verma CS, Lopez-Bigas N, Scaltriti M, Arnedos M, Saura C, Serra V.
Author Correction : High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer.
Nature communications. 2022 Sep 7;13(1):5258. doi: 10.1038/s41467-022-32828-6.
PMID: 36071033

167. **Grumberg V**, Roze S, Chevalier J, Borrill J, Gaudin A-F, Branchoux S. A Review of Overall Survival Extrapolations of Immune-Checkpoint Inhibitors Used in Health Technology Assessments by the French Health Authorities – Erratum. *International Journal of Technology Assessment in Health Care*. 2022 May 17;38(1):e38.doi: 10.1017/S0266462322000228. PMID: 35577771
168. Bigot J, Godmer A, Prudenté L, Angebault C, Brissot E, Bige N, Voiriot G, Leger PL, Petit-Hoang C, **Atallah S**, Gouache E, Senghor Y, Valot S, Hennequin C, Guitard J. Diagnosis of mucormycosis using an intercalating dye-based quantitative PCR. *Medical Mycology*. 2022 Mar 12;60(4):myac015. doi: 10.1093/mmy/myac015. PMID: 35188208